152 related articles for article (PubMed ID: 26596375)
1. Stable isotope method to measure drug release from nanomedicines.
Skoczen S; McNeil SE; Stern ST
J Control Release; 2015 Dec; 220(Pt A):169-174. PubMed ID: 26596375
[TBL] [Abstract][Full Text] [Related]
2. Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion.
Stern ST; Zou P; Skoczen S; Xie S; Liboiron B; Harasym T; Tardi P; Mayer LD; McNeil SE
J Control Release; 2013 Dec; 172(2):558-67. PubMed ID: 23664969
[TBL] [Abstract][Full Text] [Related]
3. Improved Ultrafiltration Method to Measure Drug Release from Nanomedicines Utilizing a Stable Isotope Tracer.
Skoczen SL; Stern ST
Methods Mol Biol; 2018; 1682():223-239. PubMed ID: 29039106
[TBL] [Abstract][Full Text] [Related]
4. Distinguishing Pharmacokinetics of Marketed Nanomedicine Formulations Using a Stable Isotope Tracer Assay.
Skoczen SL; Snapp KS; Crist RM; Kozak D; Jiang X; Liu H; Stern ST
ACS Pharmacol Transl Sci; 2020 Jun; 3(3):547-558. PubMed ID: 32566919
[TBL] [Abstract][Full Text] [Related]
5. A novel aqueous parenteral formulation of docetaxel using prodrugs.
Park MH; Keum CG; Song JY; Kim D; Cho CW
Int J Pharm; 2014 Feb; 462(1-2):1-7. PubMed ID: 24370840
[TBL] [Abstract][Full Text] [Related]
6. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
Zhigaltsev IV; Winters G; Srinivasulu M; Crawford J; Wong M; Amankwa L; Waterhouse D; Masin D; Webb M; Harasym N; Heller L; Bally MB; Ciufolini MA; Cullis PR; Maurer N
J Control Release; 2010 Jun; 144(3):332-40. PubMed ID: 20202473
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel prodrug self-assembled nanosystem: Synthesis, formulation and cytotoxicity.
Jing F; Guo Q; Xu W; Qu H; Sui Z
Bioorg Med Chem Lett; 2018 Feb; 28(4):826-830. PubMed ID: 29395972
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and Biological Evaluation of a Novel Water-soluble Prodrug of Docetaxel with Amino Acid as a Linker.
Ma H; Chen G; Wang T; Li Q; Liu Y
Chem Biol Drug Des; 2016 Sep; 88(3):363-9. PubMed ID: 27061863
[TBL] [Abstract][Full Text] [Related]
9. Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo.
Feng L; Wu H; Ma P; Mumper RJ; Benhabbour SR
Int J Nanomedicine; 2011; 6():2545-56. PubMed ID: 22072889
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine: enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation.
Gan CW; Chien S; Feng SS
Curr Pharm Des; 2010 Jul; 16(21):2308-20. PubMed ID: 20618152
[TBL] [Abstract][Full Text] [Related]
11. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.
Pan D; Schmieder AH; Wang K; Yang X; Senpan A; Cui G; Killgore K; Kim B; Allen JS; Zhang H; Caruthers SD; Shen B; Wickline SA; Lanza GM
Theranostics; 2014; 4(6):565-78. PubMed ID: 24723979
[TBL] [Abstract][Full Text] [Related]
13. Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin.
Kim TK; Kim IS; Yoo HH
Biomed Chromatogr; 2013 Mar; 27(3):306-10. PubMed ID: 22837069
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation.
Yin YM; Cui FD; Mu CF; Choi MK; Kim JS; Chung SJ; Shim CK; Kim DD
J Control Release; 2009 Dec; 140(2):86-94. PubMed ID: 19709639
[TBL] [Abstract][Full Text] [Related]
15. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
Lee SW; Yun MH; Jeong SW; In CH; Kim JY; Seo MH; Pai CM; Kim SO
J Control Release; 2011 Oct; 155(2):262-71. PubMed ID: 21704664
[TBL] [Abstract][Full Text] [Related]
16. A unique highly hydrophobic anticancer prodrug self-assembled nanomedicine for cancer therapy.
Ren G; Jiang M; Xue P; Wang J; Wang Y; Chen B; He Z
Nanomedicine; 2016 Nov; 12(8):2273-2282. PubMed ID: 27389147
[TBL] [Abstract][Full Text] [Related]
17. Development of a docetaxel micellar formulation using poly(ethylene glycol)-polylactide-poly(ethylene glycol) (PEG-PLA-PEG) with successful reconstitution for tumor targeted drug delivery.
Sim T; Kim JE; Hoang NH; Kang JK; Lim C; Kim DS; Lee ES; Youn YS; Choi HG; Han HK; Weon KY; Oh KT
Drug Deliv; 2018 Nov; 25(1):1362-1371. PubMed ID: 29869563
[TBL] [Abstract][Full Text] [Related]
18. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake.
Cho HJ; Park JW; Yoon IS; Kim DD
Int J Nanomedicine; 2014; 9():495-504. PubMed ID: 24531717
[TBL] [Abstract][Full Text] [Related]
19. Probing the Superiority of Diselenium Bond on Docetaxel Dimeric Prodrug Nanoassemblies: Small Roles Taking Big Responsibilities.
Zuo S; Sun B; Yang Y; Zhou S; Zhang Y; Guo M; Sun M; Luo C; He Z; Sun J
Small; 2020 Nov; 16(45):e2005039. PubMed ID: 33078579
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of docetaxel solubility via conjugation of formulation-compatible moieties.
Huynh L; Leroux JC; Allen C
Org Biomol Chem; 2009 Sep; 7(17):3437-46. PubMed ID: 19675898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
